Explore the latest news from Khondrion and its team.
Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that the...
Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that...
Khondrion, a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that it has...
Designation granted for the treatment of MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes) syndrome. Khondrion, a...
NIJMEGEN, the Netherlands – Wednesday July 1st, 2020 Khondrion, a clinical-stage pharmaceutical company discovering and developing therapies...
Khondrion highlights potential role of inflammatory lipid modulator prostaglandin E2 in COVID-19 disease and proposes potential...
2020 – A Year in Review As a new year approaches, Khondrion’s CEO Jan Smeitink reflects on 2020 and the progress Khondrion has made in its research...
1. Tell us about your role as Chief Early Development Officer at Khondrion. There are a lot of different aspects to my role. I help to steer the...
Estimated to affect more than 400 million people around the world, diabetes is one of the most common chronic disorders, with a range of different...
Mitochondrial diseases are a clinically, biochemically and genetically heterogeneous group of disorders. Signs, symptoms and the organs involved can...
Simple functions such as blinking and breathing are actions that we take for granted. However, for those living with Leigh...
1. Tell us about your career before joining Khondrion.I qualified as a Medical Doctor from the University of Utrecht and worked clinically in the...
